What new treatments for Neuroendocrine Tumors are being developed in 2026

New Neuroendocrine Tumor Treatments in Development (2026)

I appreciate your question about emerging treatments. Based on the most current NCCN Guidelines (Version 3.2025) and available medical literature, here's what's on the horizon for neuroendocrine tumor (NET) care:

Recently Approved & Emerging Therapies

Cabozantinib (Cabometyx) According to NCCN Guidelines, cabozantinib represents a newer targeted therapy option that has shown promise in advanced NETs. This is a multi-targeted kinase inhibitor that works against several cancer-driving pathways simultaneously.

Peptide Receptor Radionuclide Therapy (PRRT) Advances The NCCN Guidelines highlight ongoing refinement of lutetium Lu-177 dotatate (Lutathera) therapy, which uses radioactive particles to target somatostatin receptors on NET cells. Recent studies show improved outcomes when combined with long-acting somatostatin analogs (SSAs) like octreotide LAR or lanreotide.

Immunotherapy Combinations NCCN Guidelines note that nivolumab plus ipilimumab (dual checkpoint inhibitors) are being explored for high-grade neuroendocrine neoplasms, particularly for patients with specific genetic markers like MSI-H (microsatellite instability-high) or TMB-H (tumor mutational burden-high).

Targeted Therapies Based on Genetic Mutations

The guidelines emphasize that treatment is increasingly personalized based on tumor genetics:

• NTRK fusion-positive NETs: Entrectinib and larotrectinib (TRK inhibitors)
• RET fusion-positive NETs: Selpercatinib (RET inhibitor)
• BRAF V600E mutations: Dabrafenib plus trametinib
• mTOR pathway mutations: Everolimus continues to be refined

Clinical Trials to Watch

According to NCCN Guidelines, several areas are actively being researched:

1. Combination approaches - Pairing chemotherapy with targeted agents or immunotherapy
2. Higher-dose SSA strategies - Testing whether increased doses of octreotide LAR or lanreotide improve outcomes
3. Novel chemotherapy combinations - Including FOLFIRINOX and oxaliplatin-based regimens for aggressive NETs

Important Context

What's actually "new" in 2026? The reality is that most transformative NET treatments approved in recent years (like cabozantinib and enhanced PRRT protocols) are now being refined and optimized rather than completely new drugs emerging. The field is moving toward:

• Better patient selection - Using biomarkers to predict who will respond to specific treatments
• Combination strategies - Using multiple drugs together for better results
• Personalized medicine - Tailoring treatment based on individual tumor genetics

Questions to Ask Your Oncologist

Since treatment decisions depend heavily on YOUR specific tumor characteristics:

1. "Has my tumor been tested for genetic mutations (NTRK, RET, BRAF, mTOR, MSI-H, TMB-H)?" - This determines which targeted therapies might work best
2. "Is my tumor somatostatin receptor-positive?" - This affects eligibility for PRRT and SSA therapy
3. "Are there clinical trials available for my specific tumor type and stage?" - Trials often provide access to newer combinations before standard approval
4. "What combination approaches would you recommend given my tumor's grade and genetics?" - Modern NET treatment often uses multiple therapies together
5. "How do you monitor for treatment response and side effects?" - This helps you understand what to expect

Where to Find Current Information

• NCCN Guidelines (updated regularly) - The most current treatment recommendations
• ClinicalTrials.gov - Search for "neuroendocrine tumor" to find active trials in your area
• The Neuroendocrine Cancer Society - Patient-focused resources on emerging treatments
• Your oncologist's institution - Academic cancer centers often have access to cutting-edge trials

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.